Clinical specimens from COVID-19 positive swabs (Ethics statement, ECS1166/2020) and SARS-CoV-2 viruses from repositories (BEI Resources, Manassas, VA, USA; CFAR/NIBSC; Nr-52281, Nr-52282, NR-52286) were propagated according to the manufacturer’s instructions and used subsequently in neutralization assays.

Note: The content above has been extracted from a research article, so it may not display correctly.

Please log in to submit your questions online.
Your question will be posted on the Bio-101 website. We will send your questions to the authors of this protocol and Bio-protocol community members who are experienced with this method. you will be informed using the email address associated with your Bio-protocol account.

We use cookies on this site to enhance your user experience. By using our website, you are agreeing to allow the storage of cookies on your computer.